Want to see JP:4577 full AI Analyst Report?
Total Valuation
Daito Pharmaceutical Co., Ltd. has a market cap or net worth of ¥37.50B. The enterprise value is ¥42.94B.
Market Cap¥37.50B
Enterprise Value¥42.94B
Share Statistics
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,854,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Daito Pharmaceutical Co., Ltd.’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.48%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.04
Return on Invested Capital (ROIC)4.48%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee47.20M
Profits Per Employee2.95M
Employee Count1,073
Asset Turnover0.69
Inventory Turnover2.48
Valuation Ratios
The current PE Ratio of Daito Pharmaceutical Co., Ltd. is 12.1. Daito Pharmaceutical Co., Ltd.’s PEG ratio is 0.15.
PE Ratio12.1
PS Ratio0.68
PB Ratio0.65
Price to Fair Value0.65
Price to FCF6.19
Price to Operating Cash Flow0.00
PEG Ratio0.15
Income Statement
In the last 12 months, Daito Pharmaceutical Co., Ltd. had revenue of 50.65B and earned 3.16B in profits. Earnings per share was 107.46.
Revenue50.65B
Gross Profit9.90B
Operating Income3.64B
Pretax Income4.07B
Net Income3.16B
EBITDA8.02B
Earnings Per Share (EPS)107.46
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Daito Pharmaceutical Co., Ltd. pays an annual dividend of ¥22.5, resulting in a dividend yield of 2.75%
Dividend Per Share¥22.5
Dividend Yield2.75%
Payout Ratio57.02%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.28
52-Week Price Change16.72%
50-Day Moving Average1.22K
200-Day Moving Average1.28K
Relative Strength Index (RSI)63.34
Average Volume (3m)63.87K
Important Dates
Daito Pharmaceutical Co., Ltd. upcoming earnings date is Oct 8, 2026, TBA (Confirmed).
Last Earnings DateJul 10, 2026
Next Earnings DateOct 8, 2026
Ex-Dividend Date―
Financial Position
Daito Pharmaceutical Co., Ltd. as a current ratio of 2.62, with Debt / Equity ratio of 17.57%
Current Ratio2.62
Quick Ratio1.44
Debt to Market Cap0.21
Net Debt to EBITDA1.04
Interest Coverage Ratio27.98
Taxes
In the past 12 months, Daito Pharmaceutical Co., Ltd. has paid 928.00M in taxes.
Income Tax928.00M
Effective Tax Rate0.23
Enterprise Valuation
Daito Pharmaceutical Co., Ltd. EV to EBITDA ratio is 5.30, with an EV/FCF ratio of 7.70.
EV to Sales0.84
EV to EBITDA5.30
EV to Free Cash Flow7.70
EV to Operating Cash Flow4.54
Balance Sheet
Daito Pharmaceutical Co., Ltd. has ¥1.87B in cash and marketable securities with ¥10.15B in debt, giving a net cash position of -¥8.28B billion.
Cash & Marketable Securities¥1.87B
Total Debt¥10.15B
Net Cash-¥8.28B
Net Cash Per Share-¥286.92
Tangible Book Value Per Share¥1.80K
Margins
Gross margin is 19.54%, with operating margin of 7.18%, and net profit margin of 6.24%.
Gross Margin19.54%
Operating Margin7.18%
Pretax Margin8.03%
Net Profit Margin6.24%
EBITDA Margin15.84%
EBIT Margin7.18%
Analyst Forecast
The average price target for Daito Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast0.01%
EPS Growth Forecast71.34%